0.420
-0.02 (-4.02%)
| Previous Close | 0.438 |
| Open | 0.425 |
| Volume | 503,591 |
| Avg. Volume (3M) | 134,116 |
| Market Cap | 16,074,659 |
| Price / Sales | 1.75 |
| Price / Book | 0.240 |
| 52 Weeks Range | |
| Earnings Date | 12 May 2025 - 16 May 2025 |
| Operating Margin (TTM) | -887.33% |
| Diluted EPS (TTM) | -1.65 |
| Quarterly Revenue Growth (YOY) | -100.00% |
| Total Debt/Equity (MRQ) | 44.07% |
| Current Ratio (MRQ) | 3.20 |
| Operating Cash Flow (TTM) | -61.29 M |
| Levered Free Cash Flow (TTM) | -37.54 M |
| Return on Assets (TTM) | -32.88% |
| Return on Equity (TTM) | -74.28% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bearish |
| Biotechnology (Global) | Mixed | Bearish | |
| Stock | Bolt Biotherapeutics, Inc. | Mixed | Bearish |
AIStockmoo Score
| Analyst Consensus | 2.5 |
| Insider Activity | NA |
| Price Volatility | 0.5 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | -1.0 |
| Average | 1.13 |
|
Bolt Biotherapeutics Inc is a clinical-stage immuno-oncology company. It is developing tumor-targeted therapies that leverage the power of the innate and adaptive immune systems. The company's pipeline candidates are built on our deep expertise in myeloid biology and cancer drug development. The company's proprietary Boltbody ISAC platform technology combines tumor-targeting antibodies with immune-stimulating linker-payloads. The company's pipeline consists of BDC-1001, BDC-3042, and Next-Gen ISAC. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 2.25% |
| % Held by Institutions | 48.10% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Pivotal Bioventure Partners Investment Advisor Llc | 31 Dec 2024 | 1,891,467 |
| 52 Weeks Range | ||
| Median | 1.25 (197.62%) | |
| Total | 1 Hold | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Stifel | 25 Mar 2025 | 1.25 (197.62%) | Hold | 0.420 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 08 May 2025 | Announcement | Bolt Biotherapeutics to Host KOL Conference Call and Webcast to Discuss BDC-3042 Phase 1 Results and Corporate Updates |
| 30 Apr 2025 | Announcement | Bolt Biotherapeutics Presents Preclinical Results for Next-Generation Boltbody™ ISACs targeting CEA and PD-L1 at AACR Annual Meeting 2025 |
| 25 Apr 2025 | Announcement | Bolt Biotherapeutics Presents Results from the Phase 1 Dose-Escalation Clinical Study of BDC-3042 at AACR Annual Meeting 2025 |
| 25 Mar 2025 | Announcement | Bolt Biotherapeutics to Present Data from Phase 1 Dose-Escalation Clinical Study of BDC-3042 at AACR Annual Meeting 2025 |
| 24 Mar 2025 | Announcement | Bolt Biotherapeutics Reports Fourth Quarter and Full-Year 2024 Financial Results and Provides Business Update |
| 25 Feb 2025 | Announcement | Bolt Biotherapeutics to Participate in Upcoming March Conferences |
| 11 Feb 2025 | Announcement | Bolt Biotherapeutics, Inc. Provides Update on Global Cancer Immunotherapy Co-Development with Toray Industries, Inc. |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |